Matrix Laboratories Announces Appointment of Jagdish Dore’ as CEO

Secunderabad, India –Feb. 27, 2008–Matrix Laboratories Limited today announced the appointment of Jagdish Viswanath Dore’ as CEO. Mr. Dore’ will assume the responsibilities of Rajiv Malik who became Executive Vice President and Head of Global Technical Operations for Mylan Inc. (NYSE: MYL) in October 2007and has been serving as interim CEO for Matrix, a majority-owned subsidiary of Mylan. Mr. Malik will be relocated to the U.S in connection with his employment by Mylan.

Mr. Dore’ joins Matrix after a distinguished 29 year career with Sandoz most recently as Managing Director and India Country Head. In this role, Mr. Dore’ was responsible for all of Sandoz’s operations in India including global development and manufacturing; local and export sales; day-to-day operations; and technical operations in the Asia Pacific region. He was previously responsible for business operations in the Asia Pacific cluster and involved in the startup of Novartis Enterprises Private Limited (now Sandoz), Novartis Consumer Health India Private Limited and Master Builders Technology India Private Limited, India.

Matrix Chairman Robert J. Coury said: “Jagdish’s impressive industry reputation is well known, and I believe he will be a huge asset to Matrix as it continues to expand its integral role in support of Mylan’s global platform. I have every confidence that Jagdish will ensure that Matrix continues its strong growth and supports Mylan in becoming the world’s leading, fully-integrated generic pharmaceuticals company.”

N. Prasad, Matrix’s Vice Chairman, commented, “I have known Jagdish for some time, and I am absolutely delighted that he will be assuming Rajiv’s role as CEO of Matrix. During his tenure at Sandoz, Jagdish was responsible for managing the company’s 1,800 employees based in India along with developing a rapidly growing business across the Asia Pacific region. He brings a great deal of experience on a strategic and operational level that will be invaluable to Matrix as it strengthens its leadership in active pharmaceutical ingredients (API), further develops its finished dosage form (FDF) capabilities and continues to grow its antiretroviral (ARV) business.”

Mr. Dore’ said: “Matrix is an established, highly respected and high-quality company in the pharmaceuticals industry both in India and world-wide. It is only enhanced by being part of Mylan. I look forward to leading Matrix into the next phase of its growth and working with the Mylan and Matrix senior management teams to further align our organizations and leverage the opportunities available to us in the global generics market.”

Mr. Dore’ earned a Bachelor of Technology degree from the Indian Institute of Technology, Chennai, and a postgraduate degree in business management from the Xavier Institute in Jamshedpur specializing in marketing.

Matrix Laboratories Limited, a subsidiary of Mylan Inc., USA, is a public limited company listed on BSE and NSE, and is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms. Matrix is one of the fastest growing API manufacturers in India and focuses on regulated markets such as U.S. and EU. The company has a wide range of products in CNS, anti-bacterial, anti-AIDS, anti-asthmatic, cardiovascular, gastrointestinal, anti-fungal, pain management and life style related therapeutic segments. All API and FDF manufacturing facilities of the Matrix are approved by the US FDA. For more information about Matrix, please visit www.matrixlabsindia.com